

# Ischemic Heart Disease & Chronic Heart Failure in the Elderly

## *Bibliography of One Hundred Key References*

selected by **Steven P. Schulman\***, MD; **Edward G. Lakatta†**, MD; **Gary Gerstenblith\***, MD

\*Johns Hopkins University School of Medicine - Baltimore, Md - USA

†Gerontology Research Center - Laboratory of Cardiovascular Science - Baltimore, Md - USA - e-mail: lakatta@grc.nia.nih.gov

- 
- Abete P, Ferrara N, Cacciatore F.** *Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart?*  
**J Am Coll Cardiol.** 1997;30:947-954.
- 
- ACE Inhibitor Myocardial Infarction Collaborative Group.** *Indications for ACE inhibitors in the early treatment of acute myocardial infarction.*  
**Circulation.** 1998;97:2202-2212.
- 
- Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.** *Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.*  
**Lancet.** 1993;342:821-828.
- 
- Alexander KP, Chen AY, Roe MT, et al.** *Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.*  
**JAMA.** 2005;294:3108-3116.
- 
- Alexander KP, Newby LK, Armstrong PW, et al.** *Acute coronary care in the elderly, Part II. ST-segment-elevation myocardial infarction.*  
**Circulation.** 2007;115:2570-2589.
- 
- Alexander KP, Newby LK, Cannon CP, et al.** *Acute coronary care in the elderly, Part I. Non-ST-segment-elevation acute coronary syndromes.*  
**Circulation.** 2007;115:2549-2569.
- 
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.** *Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).*  
**JAMA.** 2002;288:2981-2997.
- 
- Anavekar NS, McMurray JJ, Velazquez EJ, et al.** *Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.*  
**N Engl J Med.** 2004;351:1285-1295.
- 
- Anderson JL, Adams CD, Antman EM, et al; Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction.** *ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.*  
**Circulation.** 2007;116:803-877.
-

**Bibliography of One Hundred Key References**

---

<b>Antithrombotic Trialists' Collaboration.</b>	<i>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.</i> <b>BMJ.</b> 2002;324:71-86.
<b>Anversa P, Kajstura J, Leri A, Bolli R.</b>	<i>Life and death of cardiac stem cells: a paradigm shift in cardiac biology.</i> <b>Circulation.</b> 2006;113:1451-1463.
<b>Anversa P, Rota M, Urbanek K, et al.</b>	<i>Myocardial aging—a stem cell problem.</i> <b>Basic Res Cardiol.</b> 2005;100:482-493.
<b>Asahara T, Murohara T, Sullivan A, et al.</b>	<i>Isolation of putative progenitor endothelial cells for angiogenesis.</i> <b>Science.</b> 1997;275:964-967.
<b>Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators.</b>	<i>Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.</i> <b>Lancet.</b> 2001;358:605-613.
<b>Bach RG, Cannon CP, Weintraub WS, et al.</b>	<i>The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes.</i> <b>Ann Intern Med.</b> 2004;141:186-195.
<b>Ballard VL, Edelberg JM.</b>	<i>Stem cells and the regeneration of the aging cardiovascular system.</i> <b>Circ Res.</b> 2007;100:1116-1127.
<b>Barron HV, Bowlby LJ, Breen T, et al; National Registry of Myocardial Infarction 2 Investigators.</b>	<i>Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.</i> <b>Circulation.</b> 1998;97:1150-1156.
<b>Batchelor WB, Anstrom KJ, Muhlbaier LH, et al.</b>	<i>Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians (National Cardiovascular Network Collaboration).</i> <b>J Am Coll Cardiol.</b> 2000;36:723-730.
<b>Bhatt DL, Roe MT, Peterson ED, et al; CRUSADE Investigators.</b>	<i>Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.</i> <b>JAMA.</b> 2004;292:2096-2104.
<b>Boden WE, O'Rourke RA, Teo KK, et al.</b>	<i>Optimal medical therapy with or without PCI for stable coronary disease.</i> <b>N Engl J Med.</b> 2007;356:1503-1516.
<b>Boengler K, Buechert A, Heinen Y, et al.</b>	<i>Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice.</i> <b>Circ Res.</b> 2008;102:131-135.
<b>Boersma E, Harrington RA, Moliterno DJ, et al.</b>	<i>Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.</i> <b>Lancet.</b> 2002;359:189-198.
<b>Cannon CP, Braunwald E, McCabe CH, et al.</b>	<i>Intensive versus moderate lipid lowering with statins after acute coronary syndromes.</i> <b>N Engl J Med.</b> 2004;350:1495-1504.



- 
- Cannon CP, Weintraub WS, Demopoulos LA, et al; TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators.** *Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.* **N Engl J Med.** 2001;344:1879-1887.
- 
- Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.** *Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.* **N Engl J Med.** 2001;345:494-502.
- 
- de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F.** *Reperfusion therapy in elderly patients with acute myocardial infarction.* **J Am Coll Cardiol.** 2002;39:1723-1728.
- 
- Domanski M, Norman J, Wolz M, Mitchell G, Pfeffer M.** *Cardiovascular risk assessment using pulse pressure in the first national health and nutrition examination survey (NHANES I).* **Hypertension.** 2001;38:793-797.
- 
- Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J.** *Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE).* **Lancet.** 2002;359:373-377.
- 
- Eagle KA, Lim MJ, Dabbous OH, et al.** *A validated prediction model for all forms of acute coronary syndrome.* **JAMA.** 2004;291:2727-2733.
- 
- Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S.** *Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function.* **Circ Res.** 2002;90:e89-e93.
- 
- Erusalimsky JD, Kurz DJ.** *Endothelial cell senescence.* **Handb Exp Pharmacol.** 2006;176:213-248.
- 
- Fibrinolytic Therapy Trialists' Collaborative Group.** *Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.* **Lancet.** 1994;343:311-322.
- 
- Flather MD, Yusuf S, Køber L, et al.** *Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.* **Lancet.** 2000;355:1575-1581.
- 
- Forette F, Seux ML, Staessen JA, et al.** *Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.* **Lancet.** 1998;352:1347-1351.
- 
- Fox KA, Poole-Wilson RA, Clayton TC, et al; Randomized Intervention Trial of unstable Angina (RITA) investigators.** *Interventional versus conservative treatment for patients with unstable angina or non-ST segment elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial.* **Lancet.** 2002;360:743-751.
- 
- Fragmin and Fast Revascularization during inStability in coronary artery disease (FRISC II) Investigators.** *Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multi-centre study.* **Lancet.** 1999;354:708-715.
-

**Bibliography of One Hundred Key References**

---

- Goldberg RJ, Gore JM, Gurwitz JH, et al.** *The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study.* **Am Heart J.** 1989;117:543-549.
- 
- Gore JM, Granger CB, Simoons ML, et al.** *Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I Trial.* **Circulation.** 1995;92:2811-2818.
- 
- Gottlieb SS, McCarter RJ, Vogel RA.** *Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction.* **N Engl J Med.** 1998;339:489-497.
- 
- Grines CL, Browne KF, Marco J, et al.** *A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction.* **N Engl J Med.** 1993;328:672-679.
- 
- Gundersen T, Abrahamsen AM, Kjekshus J, Ronnevik PK; Norwegian Multicentre Study Group.** *Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction.* **Circulation.** 1982;66:1179-1182.
- 
- GUSTO V Investigators.** *Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.* **Lancet.** 2001;357:1905-1914.
- 
- Harris MI, Flegal KM, Cowie CC, et al.** *Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.* **Diabetes Care.** 1998;21:518-524.
- 
- Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes DR.** *Cardiogenic shock complicating acute coronary syndromes.* **Lancet.** 2000;356:749-756.
- 
- Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C.** *Impaired progenitor cell activity in age-related endothelial dysfunction.* **J Am Coll Cardiol.** 2005;45:1441-1448.
- 
- Hill JM, Zalos G, Halcox JP, et al.** *Circulating endothelial progenitor cells, vascular function, and cardiovascular risk.* **N Engl J Med.** 2003;348:593-600.
- 
- Hochman JS, Sleeper LA, Webb JG, et al.** *Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.* **JAMA.** 2006;295:2511-2515.
- 
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.** *Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction.* **Lancet.** 1988;2:349-360.
- 
- Kahler J, Lutke M, Weckmuller J.** *Coronary angioplasty in octogenarians. Quality of life and costs.* **Eur Heart J.** 1999;20:1791-1798.
- 
- Kannel WB.** *Elevated systolic blood pressure as a cardiovascular risk factor.* **Am J Cardiol.** 2000;85:251-255.
-



- 
- Kastrati A, Mehilli J, Neumann FJ, et al; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators.** *Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.*  
**JAMA.** 2006;295:1531-1538.
- 
- Keeley EC, Boura JA, Grines CL.** *Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.*  
**Lancet.** 2003;361:13-20.
- 
- Khot UN, Jia G, Moliterno DJ, et al.** *Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes.*  
**JAMA.** 2003;290:2174-2181.
- 
- Kober L, Torp-Pedersen C, Carlsen JE, et al; Trandolapril Cardiac Evaluation (TRACE) Study Group.** *A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.*  
**N Engl J Med.** 1995;333:1670-1676.
- 
- LaCroix AZ, Lang J, Scherr P, et al.** *Smoking and mortality among older men and women in three communities.*  
**N Engl J Med.** 1991;324:1619-1625.
- 
- Lakatta EG.** *Cardiovascular regulatory mechanisms in advanced age.*  
**Physiol Rev.** 1993;73:413-467.
- 
- Lakatta EG, Levy D.** *Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease.*  
**Circulation.** 2003;107:139-146.
- 
- Lakatta EG, Levy D.** *Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease.*  
**Circulation.** 2003;107:346-354.
- 
- Lakatta EG.** *Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging.*  
**Circulation.** 2003;107:490-497.
- 
- Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED.** *Representation of elderly persons and women in published randomized trials of acute coronary syndromes.*  
**JAMA.** 2001;286:708-713.
- 
- Lewington S, Clark R, Qizibash N, Peto R, Collins R; Prospective Studies Collaboration.** *Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.*  
**Lancet.** 2002;360:1903-1913.
- 
- Lewis HDJ, Davis JW, Archibald DG, et al.** *Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study.*  
**N Engl J Med.** 1983;309:396-403.
- 
- Maggioni AP, Maseri A, Fresco C, et al.** *Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis.*  
**N Engl J Med.** 1993;329:1442-1448.
-

**Bibliography of One Hundred Key References**

---

- Martin I, Grotewiel ML.** *Oxidative damage and age-related functional declines.*  
**Mech Ageing Dev.** 2006;127:411-423.
- 
- Mehta RH, Granger CB, Alexander KP, Bossone E, White HD, Sketch M.** *Reperfusion strategies for acute myocardial infarction in the elderly.*  
**J Am Coll Cardiol.** 2005;45:471-478.
- 
- Mehta RH, Roe MT, Chen AY, et al.** *Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes.*  
**Arch Intern Med.** 2006;166:2027-2034.
- 
- Mehta SR, Cannon CP, Fox KA, et al.** *Routine versus selective invasive strategies in patients with acute coronary syndrome: a collaborative meta-analysis of randomized trials.*  
**JAMA.** 2005;292:2908-2917.
- 
- Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators.** *Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.*  
**Lancet.** 2001;358:527-533.
- 
- Messinger-Rapport BJ, Sprecher D.** *Prevention of cardiovascular diseases. Coronary artery disease, congestive heart failure, and stroke.*  
**Clin Geriatr Med.** 2002;18:463-483.
- 
- Mitchell GF, Moya LA, Braunwald E, et al.** *Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function.*  
**Circulation.** 1997;96:4254-4260.
- 
- Morton Hawkins C, Richardson DW, Vokonas PS; Beta-Blocker Heart Attack Trial Research Group.** *Effect of propranolol in reducing mortality in older myocardial infarction patients: the Beta-Blocker Heart Attack Trial Experience.*  
**Circulation.** 1983;67(suppl I):I194-I197.
- 
- Moscucci M, Fox KA, Cannon CP, et al; GRACE Investigators.** *Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).*  
**Eur Heart J.** 2003;24:1815-1823.
- 
- Nadelmann J, Frishman WH, Ooi WL, et al.** *Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: the Bronx Aging Study.*  
**Am J Cardiol.** 1990;66:533-537.
- 
- Najjar SS, Schulman SP, Gerstenblith G, et al.** *Age and gender affect ventricular vascular coupling during aerobic exercise.*  
**J Am Coll Cardiol.** 2004;44:611-617.
- 
- Nicod P, Gilpin E, Dittrich H, et al.** *Short-and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large population.*  
**Circulation.** 1989;79:528-536.
- 
- Orlandi A, Marcellini M, Spagnoli LG.** *Aging influences development and progression of early aortic atherosclerotic lesions in cholesterol-fed rabbits.*  
**Arterioscler Thromb Vasc Biol.** 2000;20:1123-1136.
- 
- Peterson ED, Roe MT, Mulgund J, et al.** *Association between hospital process performance and outcomes among patients with acute coronary syndromes.*  
**JAMA.** 2006;295:1912-1920.
-



- 
- Pfeffer MA, Braunwald E, Moye LA, et al.** *Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction.*  
**N Engl J Med.** 1992;327:669-677.
- 
- Pitt B, Remme W, Zannad F, et al.** *Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.*  
**N Engl J Med.** 2003;348:1309-1321.
- 
- Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al.** *Aging, progenitor cell exhaustion, and atherosclerosis.*  
**Circulation.** 2003;108:457-463.
- 
- RISC Group.** *Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.*  
**Lancet.** 1990;336:827-830.
- 
- Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators.** *The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.*  
**N Engl J Med.** 1996;335:1001-1009.
- 
- Santhanam L, Lim HK, Lim HK et al.** *Inducible NO synthase dependent S-nitrosylation and activation of arginase 1 contribute to age-related endothelial dysfunction.*  
**Circ Res.** 2007;101:692-702.
- 
- Scheubel RJ, Zorn H, Silber RE, et al.** *Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.*  
**J Am Coll Cardiol.** 2003;42:2073-2080.
- 
- Schulman SP, Becker LC, Kass DA, et al.** *L-arginine therapy in acute myocardial infarction.*  
**JAMA.** 2006;295:58-64.
- 
- SHEP Cooperative Research Group.** *Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP).*  
**JAMA.** 1991;265:3255-3264.
- 
- Stack NM.** *Smoking cessation: an overview of treatment options with a focus on varenicline.*  
**Pharmacotherapy.** 2007;27:1550-1557.
- 
- Staessen J, Fagard R, Thijs L, et al; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.** *Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.*  
**Lancet.** 1997;350:757-764.
- 
- Steinhubl SR, Berger PB, Brennan DM, Topol EJ.** *Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention.*  
**J Am Coll Cardiol.** 2006;47:939-943.
- 
- Stone GW, McLaurin BT, Cox DA, et al.** *Bivalirudin for patients with acute coronary syndromes.*  
**N Engl J Med.** 2006;355:2203-2216.
- 
- SYNERGY Trial Investigators.** *Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.*  
**JAMA.** 2004;292:45-54.
-

**Bibliography of One Hundred Key References**

---

- Taddei S, Viridis A, Mattei P, et al.** *Aging and endothelial function in normotensive subjects and patients with essential hypertension.*  
**Circulation.** 1995;111:3384-3390.
- 
- Theroux P, Ouimet H, McCans J, et al.** *Aspirin, heparin, or both to treat acute unstable angina.*  
**N Engl J Med.** 1988;319:1105-1111.
- 
- Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR.** *Lack of benefit of thrombolysis in patients with myocardial infarction who are older than 75 years.*  
**Circulation.** 2000;101:2239-2246.
- 
- Torella D, Rota M, Nurzynska D, et al.** *Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression.*  
**Circ Res.** 2004;94:514-524.
- 
- Vaitkevicius PV, Fleg JL, Engel JH, et al.** *Effects of age and aerobic capacity on arterial stiffness in healthy adults.*  
**Circulation.** 1993;88:1456-1462.
- 
- Wallentin L, Goldstein P, Armstrong PW, et al.** *Efficacy and safety of tenecteplase in combination with the low-molecular weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.*  
**Circulation.** 2003;108:135-142.
- 
- Weber KT.** *Aldosterone in congestive heart failure.*  
**N Engl J Med.** 2001;345:1689-1697.
- 
- White HD.** *Thrombolytic therapy in the elderly.*  
**Lancet.** 2000;356:2028-2030.
- 
- White HD, Barbash GI, Califf RM, et al; GUSTO-I Investigators.** *Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial.*  
**Circulation.** 1996;94:1826-1833.
- 
- Wong CK, Gao W, Raffel OC, French JK, Stewart RA, White HD.** *Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2.*  
**Lancet.** 2006;367:2061-2067.
- 
- Yuh DD, Baumgartner WA.** *Cardiac surgery in the elderly. In: Gerstenblith G, ed. Cardiovascular Disease in the Elderly.* Totowa, NJ: Humana Press; 2005.
-

---

# Instructions for authors

## GENERAL INSTRUCTIONS

---

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in English. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), **short running title**, **keywords**, and **acknowledgments**, as well as **full names** (first name, middle name(s), and last name) with **highest academic degrees** (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All **illustrations should be cited** in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International** (SI) units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
  1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg*. 1990;11:493-496.
  2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation*. 1977;56(suppl II):II161-II164.
  3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher’s editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author’s responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

## LEAD ARTICLE

---

The lead article should not exceed 30 standard typed pages (7000 to 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion**. A separate list of “**10 references of seminal papers**” as well as a separate list of “**100 Key References**” should be provided.

## RESPONDENT ARTICLES

---

Respondent articles should not exceed 15 standard typed pages (3000 to 4000 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

## SEMINAL PAPER SUMMARIES

---

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

## FASCINOMA CARDIOLOGICA ARTICLES

---

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.